Talquetamab Consolidation After BCMA CAR-T
Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
- Myeloma Service
- 23-072
What will happen during the trial?
All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 17 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Janssen Pharmaceuticals
- Tags
- Bispecific Antibody, GPRC5D, Post-CAR T
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1778
- NCT Identifier
- NCT06066346
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.